MedscapeLIVE’s Post

One of our unique offerings is to help clients identify optimal pairings of bispecific antibodies (bsAbs) via the Quick ‘n’ Clean platform. An innovative platform for HTP production of bsAbs, Quick 'n' Clean takes advantage of the asymmetry of bispecific antibodies, adding two affinity tags at the C-terminus, which allows for rapid purification (two affinity column and one SEC column), and ensures high purity (>99% heterodimers) bsAbs. Combining speed and precision, the Quick ‘n’ Clean platform can produce 1 mg of customized bsAb with high purity from 20 mL culture in 3-4 weeks. https://lnkd.in/dw6JJgk8 #Drugdiscovery #WuXibiologics #BispecificAntibody

Characterizing bispecific antibodies? Discovering new targets? Ensuring biotherapeutic saftey and efficacy? Perhaps we have what you need! http://ms.spr.ly/6044YdPQw #BiologicsSolutions #Biotherapeutics

Are you looking for reliable detection tools for CAR-T cells? Dextramer® reagents may provide a sensitive solution for direct detection and quantification of CAR-positive cells by flow cytometry, in accordance with the recently updated guidance on CAR-T cell products from the FDA.    Learn more by following the link in the comments!    #CARTTherapy #CellTherapy #Immunotherapy #flowcytometry 

Hallo, #Medica2023! 🇩🇪 Catch our experts at Hall 3 / E71 in Düsseldorf, Germany from November 13th - 16th. Here's a little bit about us: 1) Our expertise is in creating high quality antigens and finding antibodies even against the most difficult targets. 🎯 2) We’ve produced everything from the simplest of human IgGs to afucosylated bispecific antibodies up to recombinant growth factors. 3) Our Phage Display and HybriFree platforms can rapidly identify and characterize high-quality antibodies. Meet you there! #icosagen #antibody #antibodydisocvery #proteinproduction #bioprocessing #celllinedevelopment #gmp #manufacturing

As we advance in biopharmaceuticals, the preservation and stabilization of antibodies become pivotal. However, the freeze-drying process, whilst widely used, presents its own set of challenges. Some of which include: 💠Protein Integrity: Freeze-drying can damage antibody structure and function. A correct selection of lyoprotectants and process parameters is vital for the preservation of the structure. 💠Uniform Drying: Achieving consistent drying is crucial to maintain antibody stability. 💠Storage: Post-lyophilization, antibodies remain vulnerable to moisture. Proper storage is key to prevent degradation. If you would like to find out more about our antibody services then feel free to contact us: https://bit.ly/3H9yivP #antibodies #proteins #lyophilisation #lyophilization #BiopharmaGroup

The global antibody discovery market is on the rise, and Aridis Pharmaceuticals is leading the charge with its innovative approach to combat life-threatening infections. They harness the power of monoclonal antibodies (mAbs) to target conditions like pneumonia and COVID. What sets them apart? Their technology uses your immune system to identify mAbs that can fight infections effectively and investors have noticed as the stock is up over 10% today! Join us to learn why investors are buying! Nov 9 at 4:15 PM ET webinar with ARDS Discover how they're changing the game in the medical world. Don't miss this chance to discover their groundbreaking work! Register here: https://ow.ly/7ULt50Q1Gam Learn more and read our disclosures - https://ow.ly/aBu150Q1Gaf #StockSurge #MedicalInnovation #Webinar #InfectiousDiseases #ARDSPharmaceuticals

As biotherapeutics become more complex, clients have often asked me how to design their immunogenicity assays (ADA) to reflect any risk assessment. Immunogenicity risk assessment is becoming critical to all biotherapeutics entering clinical trials. The regulatory agencies are examining the details of these assays to assess the immunogenicity risk as they move through the phases of clinical trials. This blog explains some of the essential steps when developing an ADA assay. If you have any questions, don't hesitate to contact me. #biotherapeutics #clinicaltrials #ADA #immunogenicity"

Omnix Medical’s OMN6 Receives FDA’s Fast-Track Designation for Revolutionary Anti-Infective Jerusalem-based company, Omnix Medical, has received fast-track designation from the US FDA for its groundbreaking anti-infective, OMN6. OMN6 is a novel antimicrobial peptide derived from insect host defense peptides and has a unique mechanism of action that disrupts bacterial cell membranes. It is being evaluated for its efficacy in treating hospital-acquired bacterial pneumonia caused by Acinetobacter baumannii complex, a condition where existing treatments often fail due to antimicrobial resistance. The fast-track designation highlights the need for new antimicrobial solutions. Omnix Medical's technology leverages the innate immune system mechanisms of insects and aims to counteract life-threatening infections caused by Gram-negative bacteria. For more details please click the link! https://lnkd.in/dRTGgx6f #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

The #PositiveControl (#PC) reagent is pivotal when embarking on a new #AntiDrugAntibody (#ADA) assay. Regulatory agencies typically favor #PolyclonalPCs because they represent the #invivo #immunological response. While they have accepted #MonoclonalPCs, they often inquire about the rationale behind this choice. For straightforward #biotherapeutics, a simple explanation suffices. However, as the complexity of the #biotherapeutic increases (#Bispecific, multisite additions, etc.), the use of #MonoclonalAntibodies as PC reagents becomes more intricate. Sword Bio’s comprehensive approach ensures a well-developed assay for our clients—from start to finish. We meticulously consider all #CriticalReagents, the associated items that might be affected, and the elements we want to identify for our customers. By establishing these things early on, we prevent the need to backtrack. We address each aspect precisely and then move forward with the assay, maintaining flexibility and continuous client interaction throughout the project. Click here to learn more: https://lnkd.in/gewJ7ABU

With their clinical success in COVID-19 vaccine formulations, lipid nanoparticles (LNPs) have moved to the forefront as a delivery vehicle for mRNA vaccines and therapies. The quality and efficacy of these therapies can be directly impacted by the LNP formulation, and as such, its attributes must be monitored carefully. Confident detection of LNP raw materials and related impurities based on a combination of CAD and HRAM-MS using UHPLC Hypersil GOLD C8 LC Column